©2022 Stanford Medicine
Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma
Trial ID: NCT00070291
RATIONALE: Cyclosporine may help the immune system slow the growth of angioimmunoblastic T-cell lymphoma. PURPOSE: This phase II trial is studying how well cyclosporine works in treating patients with recurrent or refractory angioimmunoblastic T-cell lymphoma.
A Phase II Study of Cyclosporine in the Treatment of Angioimmunoblastic T-Cell Lymphoma
- Diagnosis of angioimmunoblastic T-cell lymphoma (recurrent or refractory) based on
- At least one objective measurable or evaluable disease parameter.
- Have failed at least one type of treatment: chemotherapy, auto-transplant, or steroid
treatment. Patients may not receive concurrent chemotherapy.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
- Adequate renal function as indicated by creatinine <= 1.5 the upper limit of normal
- Adequate liver function as indicated by alkaline phosphatase, Aspartate
Aminotransferase (AST), and Alanine Aminotransferase (ALT) <= 2x the upper limit of
- Total bilirubin <= 2x the upper limit of normal.
- Age 18 or older.
- Prior cyclosporine or Tacrolimus (FK506).
- Prior allogeneic transplant.
- Evidence of active infection.
- Congestive heart failure, kidney failure, liver failure, or other severe
- Evidence of active neurological impairment.
- Previous history of hypersensitivity to cyclosporine and/or Cremorphor EL
- History of other malignancies (other than cured carcinomas in situ of the cervix or
basal cell carcinoma of the skin).
- pregnant or breastfeeding women.
- Human immunodeficiency virus (HIV) positive.
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office